Implementing treatment guidelines for type 2 diabetes in primary care

Postgraduate Medicine

Volumn 121, Issue 2, 2009, Pages 125-138

  Brunton, Stephen ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NONE   (United States)

Author keywords

Diabetes mellitus, type 2; Insulin analogs; Oral antidiabetic drugs; Patient education; Primary health care; Treatment guidelines

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; MEGLITINIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT;

CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DIET THERAPY; GLYCEMIC CONTROL; HUMAN; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; REVIEW; PATIENT CARE; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; UNITED STATES;

DIABETES MELLITUS, TYPE 2; GUIDELINE ADHERENCE; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; PATIENT-CENTERED CARE; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; UNITED STATES;

EID: 64849089484     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.03.1985     Document Type: Review

References (52)

1. Centers for Disease Control and Prevention. National diabetes fact sheet. 2007. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Accessed July 22, 2008.
2. Rodbard HW, Blonde L, Braithwaite SS; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):1-68.
3. American Diabetes Association. Standards of medical care in diabetes 2008. Diabetes Care. 2008;31(suppl 1):S12-S54.
4. Jellinger PS, Davidson JA, Blonde L, et al. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007;13(3):260-268. Revision April 2008.
5. Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care. 2008;31(1):102-104.
6. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Altitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-2679. (Pubitemid 43951158)
7. Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110(2):214-219. (Pubitemid 38924590)
8. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
9. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412. (Pubitemid 30609442)
10. Tuomilehto J, Lindstrom J, Eriksson JG, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350.
11. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963-1972. (Pubitemid 44156663)
12. Ong KL, Cheung BM, Man YB, et al. Treatment and control of diabetes mellitus in the United States National Health and Nutrition Examination Survey, 1999-2002. J Cardiometab Syndr. 2006;1(5):301-307.
13. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21(3):360-367. (Pubitemid 28101069)
14. Institute for Clinical Systems Improvement. Diagnosis and managment of type 2 diabetes mellitus in adults. Bloomington (MN), 2008.
15. LaSalle JR, Cross LB. Oral combination therapy with thiazolidinediones in type 2 diabetes. Am J Manag Care. 2006;12(14 suppl):S369-S381. (Pubitemid 44872759)
16. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
17. Tanenberg RJ. Transitioning pharmacologic therapy from oral agents to insulin for type 2 diabetes. Curr Med Res Opin. 2004;20(4):541-553. (Pubitemid 38525163)
18. Nissen SL, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471. (Pubitemid 46919772)
19. Brunton S. Insulin regimens for type 2 diabetes. Suppl J Fam Pract. 2006;10-17.
20. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-3086.
21. Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother. 2006;7(3):325-343. (Pubitemid 43263250)
22. Flood TM. Appropriate use of insulin analogs in an increasingly complex type 2 diabetes mellitus (T2DM) landscape. J Fam Pract. 2007;56(1 suppl):S1-S10; quiz S11-S12.
23. Hirsch IB, Bergenstal RM, Parkin CG, Wright E, Buse JB. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005;23:78-86. (Pubitemid 40965048)
24. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206. (Pubitemid 47057766)
25. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147(6):386-399.
26. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26(3):784-790. (Pubitemid 36929344)
27. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632-2637. (Pubitemid 44912190)
28. Palumbo PJ. The case for insulin treatment early in type 2 diabetes. Cleve Clin J Med. 2004;71(5):385-386, 391-392, 394 passim. (Pubitemid 38821198)
29. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591.
30. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
31. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
32. Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;260(2):129-139.
33. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358(24):2630-2633.
34. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008;31(1):173-175.
35. Januvia [package insert]. Whitehouse Station, NJ: Merck, Sharp and Dolime Ltd; February 2008.
36. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-larget trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29(6):1269-1274. (Pubitemid 44125921)
37. Haak T, Tiengo A, Draeger L, Suntum M, Waldhäusl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7(1):56-64.
38. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51(3):408-416.
39. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-weck comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24(4):631-636. (Pubitemid 32888839)
40. Korytkowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team. A multicenler, randomized, open-label, comparative, two-period crossover trial ofpreference, efficacy, and safely profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836-2848. (Pubitemid 37510593)
41. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005;27(suppl B):S89-S100.
42. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004;27(10):2495-2497. (Pubitemid 39281409)
43. Leichter SB. Pay-for-performance contracts in diabetes care. Clin Diabetes. 2006;24:56-59.
44. Watts SA. Clinical standards for diabetes care. An update. Adv Nurse Pract. 2001;9(5):65-68.
45. Blonde L, Parkin CG. Internet resources to improve health care for patients with diabetes. Endocr Pract. 2006;12(suppl 1):131-137. (Pubitemid 44963628)
46. Funnell MM, Anderson RM, Nwankwo R, et al. A study of certified diabetes educators: influences and barriers. Diabetes Educ. 2006;32(3):359-362, 364-366, 368-372.
47. Mulcahy K, Peeples M, Tomky D, Weaver T. National Diabetes Education Outcomes System: application to practice. Diabetes Educ. 2000;26(6):957-964.
48. Piatt GA, Orchard TJ, Emerson S, et al. Translating the chronic care model into the community: results from a randomized controlled trial of a multifaceted diabetes care intervention. Diabetes Care. 2006;29(4):811-817. (Pubitemid 44115299)
49. Siminerio LM, Piatt G, Zgibor JC. Implementing the chronic care model for improvements in diabetes care and education in a rural primary care practice. Diabetes Educ. 2005;31(2):225-234. (Pubitemid 40529011)
50. IDF Clinical Guideline Task Force. Global guidelines for type 2 diabetes. Brussels, Belgium: International Diabetes Federation; 2005:1-79.
51. Brown AF, Mangione CM, Saliba D, Sarkisian CA; California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(5 Suppl Guidelines):S265-S280.
52. Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med. 2007;147(6):417-422.